Replies to post #145979 on Biotech Values

[mcbio]

They are not excluding any of those patients in ph3.

But did RDEA specifically show positive efficacy and safety data in that patient population in Phase 2? If not, there's the potential for BCX4208 to differentiate itself from RDEA594.

All this said, I'm certainly not trying to give BCRX a pass here. As I mentioned, they don't report the p-values anywhere and they also don't specifically disclose the actual results in patients with renal impairment (just general reference to results in small study being positive and a link to clinicaltrials.gov).